Interferon, Interleukin-2, and Other Cytokines

Hematology/Oncology Clinics of North America

Volumn 28, Issue 3, 2014, Pages 571-583

  Buchbinder, Elizabeth I ^a   McDermott, David F ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Cytokines; Granulocyte macrophage colony stimulating factor; Interferon; Interleukin 2; Interleukin 21; Melanoma

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; CISPLATIN; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DACARBAZINE; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERFERON; INTERLEUKIN 2; INTERLEUKIN 21; IPILIMUMAB; MELANOMA VACCINE; PEGINTERFERON ALPHA2B; PEPTIDE VACCINE; PHOSPHOLIPID ANTIBODY; PLACEBO; VINBLASTINE;

ANEMIA; ANTIANGIOGENIC ACTIVITY; BONE MARROW TOXICITY; CANCER ADJUVANT THERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHILL; CONDYLOMA ACUMINATUM; CONFUSION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE REGIMEN; DRUG EFFICACY; FEVER; FLU LIKE SYNDROME; FLUID RETENTION; FOLLICULAR LYMPHOMA; HAIRY CELL LEUKEMIA; HEART INFARCTION; HEPATITIS B; HEPATITIS C; HUMAN; HYPERTHYROIDISM; HYPERTRANSAMINASEMIA; HYPOTENSION; HYPOTHYROIDISM; IMMUNOMODULATION; KAPOSI SARCOMA; LIVER DYSFUNCTION; LYMPH NODE METASTASIS; LYMPHOCYTOSIS; MELANOMA; MENTAL DISEASE; META ANALYSIS (TOPIC); METASTATIC MELANOMA; MULTIPLE SCLEROSIS; MYOCARDITIS; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; REVIEW; RISK REDUCTION; THROMBOCYTOPENIA; THYROID FUNCTION TEST; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; UREMIA; VITILIGO; CLINICAL TRIAL (TOPIC); DOSE RESPONSE; SKIN NEOPLASMS; SURVIVAL; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-2; MELANOMA; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84901618784     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2014.02.001     Document Type: Review

References (53)

1. Isaacs A., Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 1957, 147:258-267.
2. Ozato K., Uno K., Iwakura Y. Another road to interferon: Yasuichi Nagano's journey. JInterferon Cytokine Res 2007, 27:349-352.
3. Pestka S., Krause C.D., Walter M.R. Interferons, interferon-like cytokines, and their receptors. Immunol Rev 2004, 202:8-32.
4. Pestka S. The interferons: 50 years after their discovery, there is much more to learn. JBiol Chem 2007, 282:20047-20051.
5. Knight E., Hunkapiller M.W., Korant B.D., et al. Human fibroblast interferon: amino acid analysis and amino terminal amino acid sequence. Science 1980, 207:525-526.
6. Weissenbach J., Chernajovsky Y., Zeevi M., et al. Two interferon mRNAs in human fibroblasts: invitro translation and Escherichia coli cloning studies. Proc Natl Acad Sci USA 1980, 77:7152-7156.
7. Krause C.D., Pestka S. Historical developments in the research of interferon receptors. Cytokine Growth Factor Rev 2007, 18:473-482.
8. Darnell J.E., Kerr I.M., Stark G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994, 264:1415-1421.
9. Kirkwood J.M., Richards T., Zarour H.M., et al. Immunomodulatory effects of high-dose and low-dose interferon a2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690. Cancer 2002, 95:1101-1112.
10. Clemens M.J. Interferons and apoptosis. JInterferon Cytokine Res 2003, 23:277-292.
11. Krown S.E., Burk M.W., Kirkwood J.M., et al. Human leukocyte (alpha) interferon in metastatic malignant melanoma: the American Cancer Society phase II trial. Cancer Treat Rep 1984, 68:723-726.
12. Kirkwood J.M., Ernstoff M.S. Interferons in the treatment of human cancer. JClin Oncol 1984, 2:336-351.
13. Retsas S., Priestman T.J., Newton K.A., et al. Evaluation of human lyphoblastoid interferon in advanced malignant melanoma. Cancer 1982, 51:273-276.
14. Creagan E.T., Ahmann D.L., Frytak S., et al. Recombinant leukocyte A interferon (rIFN-aA) in the treatment of disseminated malignant melanoma. Analysis of complete and long-term responding patients. Cancer 1986, 58:2576-2578.
15. Kirkwood J.M., Strawderman M.H., Ernstoff M.S., et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. JClin Oncol 1996, 14:7-17.
16. Kirkwood J.M., Ibrahim J.G., Sondak V.K., et al. High- and low-dose interferon alfa-2b in high risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. JClin Oncol 2000, 18:2444-2458.
17. Livingston P.O., Wong G.Y.C., Adluri S., et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. JClin Oncol 1994, 12:1036-1044.
18. Kirkwood J.M., Ibrahim J.G., Sosman J.A., et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. JClin Oncol 2001, 19:2370-2380.
19. Wheatley K., Ives N., Hancock B., et al. Does adjuvant interferon-α for high-risk melanoma provide a worthwhile benefit? A meta-analysis of randomized trials. Cancer Treat Rev 2003, 29:241-252.
20. Wheatley K., Ives N., Eggermont A., International Malignant Melanoma Collaborative Group, et al. Interferon-α as adjuvant therapy for melanoma: an individual patient data meta-analysis of randomized trials. JClin Oncol 2007, 25:8526. [abstract].
21. Mocellin S., Pasquali S., Rossi C.F., et al. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. JNatl Cancer Inst 2010, 102:493-501.
22. Eggermont A.M., Suciu S., Santinami M., et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomized phase III trial. Lancet 2008, 372:117-126.
23. Eggermont A.M., Suciu S., Tesori A., et al. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer 2012, 48:218-225.
24. Pectasides D., Dafni U., Bafaloukos D., et al. Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma. JClin Oncol 2009, 27:939-944.
25. Agarwala S.S., Lee S.J., Flaherty L.E., et al. Randomized phase III trial of high-dose interferon alfa-2b (HDI) for 4 weeks induction only in patients with intermediate- and high-risk melanoma (Intergroup trial E1697). JClin Oncol 2011, 29(Suppl). [abstract 8505].
26. Gogas H., Ioannovich J., Dafni U., et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. NEngl J Med 2006, 16:709-718.
27. Morgan D.A., Ruscetti F.W., Gallo R. Selective invitro growth of T lymphocytes for normal human bone marrows. Science 1976, 193:1007-1008.
28. Taniguchi T., Matsui H., Fujita T., et al. Structure and expression of cloned cDNA for human interleukin-2. Nature 1983, 302:305-310.
29. Waldmann T.A., Tsudo M. Interleukin-2 receptors: biology and therapeutic potentials. Hosp Pract (Off Ed) 1987, 22:77-84. 93-4.
30. Foa R., Guarini A., Gansbacher B. IL2 treatment for cancer: from biology to gene therapy. Br J Cancer 1992, 66:992-998.
31. Rosenberg S.A., Mule J.J., Speiss P.J., et al. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. JExp Med 1985, 161:1169-1188.
32. Rosenberg S.A., Lotze M.T., Muul L.M., et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. NEngl J Med 1985, 313:1485-1492.
33. Rosenberg S.A., Lotze M.T., Muul L.M., et al. Aprogress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 or high-dose interleukin-2 alone. NEngl J Med 1987, 316:889-897.
34. Rosenberg S.A., Lotze M.T., Yang J.C., et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells of the treatment of patients with advanced cancer. JNatl Cancer Inst 1993, 85:622-632.
35. Atkins M.B., Lotze M.T., Dutcher J.P., et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. JClin Oncol 1999, 17:2105-2116.
36. Atkins M.B., Kunkel L., Sznol M., et al. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 2006, 6(Suppl 1):11-14.
37. Atkins M.B., Hsu J., Lee S., et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. JClin Oncol 2008, 10:5748-5754.
38. O'Day S.J., Atkins M.B., Baosberg P., et al. Phase II multicenter trial of maintenance biotherapy after induction concurrent biochemotherapy for patients with metastatic melanoma. J Clin Oncol 2009, 27:6207-6212.
39. Atkins M.B. Cytokine-based therapy and biochemotherapy for advanced melanoma. Clin Cancer Res 2006, 12:2353s-2358s.
40. Schwarzentruber D.J., Lawson D.H., Richards J.M., et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. NEngl J Med 2011, 364:2119-2127.
41. Dudley M.E., Jang J.C., Sherry R., et al. Adoptive cell therapy for patients with metastic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. JClin Oncol 2008, 26:5233-5239.
42. Margolin K. The clinical toxicities of high-dose interleukin-2. Therapeutic applications of interleukin-2 1993, 331-362. Marcel Dekker Inc, New York. M. Atkins (Ed.).
43. Kammula U.S., White D.E., Rosenberg S.A., et al. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer 1998, 83:797-805.
44. Phan G.Q., Attia P., Steinberg S.M., et al. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. JClin Oncol 2001, 19:3477-3482.
45. Wang E., Miller L.D., Ohnmacht G.A., et al. Prospective molecular profiling of melanoma metastasis suggests classifiers of immune responsiveness. Cancer Res 2002, 62:3581-3586.
46. Joseph R.W., Sullivan R.J., Harrell R., et al. Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma. JImmunother 2012, 35:66-72.
47. Davis I.D., Skak K., Smyth M.J., et al. Interleukin-21 signaling: functions in cancer and autoimmunity. Clin Cancer Res 2007, 13:6926-6932.
48. Petrella T.M., Tozer R., Belanger K., et al. Interleukin-21 has activity in patients with metastatic melanoma: a phase II study. JClin Oncol 2012, 30:3396-3401.
49. Dranoff G., Jaffee E., Lazenby A., et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993, 90:3539-3543.
50. Armstrong C.A., Botella R., Galloway T.H., et al. Antitumor effects of granulocyte-macrophage colony stimulating factor production by melanoma cells. Cancer Res 1996, 56:2191-2198.
51. Hodi S.F., Lee S.J., McDermott D.F., et al. Multicenter, randomized phase II trial of GM-CSF (GM) plus ipilimumab (Ipi) versus Ipi alone in metastatic melanoma: E1608. JClin Oncol 2013, 31(Suppl). [abstract CRA9007].
52. Ridolfi L., Ridolfi R. Preliminary experiences of intralesional immunotherapy in cutaneous metastatic melanoma. Hepatogastroenterology 2002, 49:335-339.
53. Andtbacka R.H., Collichio F.A., Amatruda T., et al. OPTiM: a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of unresected stage IIIB/C and IV melanoma. JClin Oncol 2013, 31(Suppl). [abstract LBA9008].